Search Result "Mixed dyslipidaemia"
Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Journal: Current Vascular Pharmacology
Volume: 8 Issue: 6 Year: 2010 Page: 820-830
Author(s): Matilda Florentin, Alexadros D. Tselepis, Moses S. Elisaf, Christos V. Rizos, Dimitri P. Mikhailidis, Evangelos N. Liberopoulos
Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Journal: Current Vascular Pharmacology
Volume: 4 Issue: 3 Year: 2006 Page: 175-183
Author(s): Anna I. Kakafika, Evagelos N. Liberopoulos, Asterios Karagiannis, Vasilios G. Athyros, Dimitri P. Mikhailidis
Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Journal: Current Vascular Pharmacology
Volume: 14 Issue: 5 Year: 2016 Page: 474-480
Author(s): Vasileios G. Chantzichristos, Aris P. Agouridis, Elisavet Moutzouri, Konstantinos Stellos, Moses S. Elisaf, Alexandros D. Tselepis
Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia
Journal: Current Pharmaceutical Design
Volume: 23 Issue: 17 Year: 2017 Page: 2496-2503
Author(s): Angelo M. Patti,Peter P. Toth,Rosaria V. Giglio,Maciej Banach,Marcello Noto,Dragana Nikolic,Giuseppe Montalto,Manfredi Rizzo
Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Journal: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Volume: 3 Issue: 3 Year: 2009 Page: 214-224
Author(s): Mena Soory
The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Journal: Current Vascular Pharmacology
Volume: 16 Issue: 4 Year: 2018 Page: 368-375
Author(s): Abdullah Shehab,Khalid Al-Rasadi,Mohamed Arafah,Ali T. Al-Hinai,Wael Al Mahmeed,Akshaya Srikanth Bhagavathula,Omer Al Tamimi,Shorook Al Herz,Faisal Al Anazi,Khalid Al Nemer,Othman Metwally,Akram Alkhadra,Mohammed Fakhry,Hossam Elghetany,Abdel Razak Medani,Afzal Hussein Yusufali,Obaid Al Jassim,Omar Al Hallaq,Fahad Omar Ahmed S. Baslaib,Mahmoud Alawadhi,Haitham Amin,Khamis Al-Hashmi,Abderrahim Oulhaj
Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Journal: Current Medicinal Chemistry
Volume: 27 Issue: 7 Year: 2020 Page: 1021-1040
Author(s): Bozidarka Zaric,Milan Obradovic,Andreja Trpkovic,Maciej Banach,Dimitri P. Mikhailidis,Esma R. Isenovic
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Journal: Current Medicinal Chemistry
Volume: 27 Issue: 27 Year: 2020 Page: 4494-4521
Author(s): Olga Panagiotopoulou,Scott T. Chiesa,Dimitrios Tousoulis,Marietta Charakida
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Journal: Current Cardiology Reviews
Volume: 6 Issue: 2 Year: 2010 Page: 112-118
Author(s): Michel P. Hermans
Fenofibrate: Metabolic and Pleiotropic Effects
Journal: Current Vascular Pharmacology
Volume: 3 Issue: 1 Year: 2005 Page: 87-98
Author(s): Vasilis Tsimihodimos, George Miltiadous, Stella S. Daskalopoulou, Dimitri P. Mikhailidis, Moses S. Elisaf